RNF126 is an E3 ubiquitin ligase. The deletion of RNF126 gene was observed in a wide range of human cancers and is correlated with improved disease-free and overall survival. These data highlight the clinical relevance of RNF126 in tumorigenesis and cancer therapy. However, the specific functions of RNF126 remain largely unknown. Homologous recombination (HR)-mediated DNA double-strand break repair is important for tumor suppression and cancer therapy resistance. Here, we demonstrate that RNF126 facilitates HR by promoting the expression of BRCA1, in a manner independent of its E3 ligase activity but depending on E2F1, a well-known transcription factor of BRCA1 promoter. In support of this result, RNF126 promotes transactivation of BRCA1 promoter by directly binding to E2F1. Most importantly, an RNF126 mutant lacking 11 amino acids that is responsible for the interaction with E2F1 has a dominant-negative effect on BRCA1 expression and HR by suppressing E2F1-mediated transactivation of BRCA1 promoter and blocking the enrichment of E2F1 on BRCA1 promoter. Lastly, RNF126 depletion leads to the increased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition. Collectively, our results suggest a novel role of RNF126 in promoting HR-mediated repair through positive regulation on BRCA1 expression by direct interaction with E2F1. This study not only offers novel insights into our current understanding of the biological functions of RNF126 but also provides a potential therapeutic target for cancer treatment.
INTRODUCTION
DNA double-strand breaks (DSBs) are the most cytotoxic forms of DNA damage. DSBs can not only be caused by replication stress but also be the principle cytotoxic lesions for ionizing radiation (IR) and chemotherapeutic drugs. Homologous recombination (HR) is one major repair pathway required for repairing DSBs. Defects in HR not only promote cancer due to the increased genomic instability, but also lead to an increased sensitivity to radiotherapy and chemotherapy.
HR is an error-free repair pathway and requires homologous donor template. Thus, in mammalian cells, HR predominantly occurs in S phase or G2 phase when the DNA template of the sister chromatid is available. Given the importance of HR in repair of DSBs during DNA replication, a deficiency in HR can cause cell proliferation defect. [1] [2] [3] BRCA1 is believed to be important for HR via promoting single-strand DNA resection by association with CtIP or acts as a recombination mediator/comediator. 4 Thus, BRCA1 is required for the recruitment of recombinase protein RAD51. In general, the function of BRCA1 in HR is considered to be one of the major mechanisms contributing to its tumor suppressor activity, 5, 6 and the cause of hypersensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors when BRCA1 is defective. 7 BRCA1 is not only mutated in familial breast and ovarian cancer patients but also exhibits low expression in sporadic cancers including breast and ovarian cancers. [8] [9] [10] A growing consensus has emerged suggesting that a large percentage of sporadic, non-inherited breast cancers are associated with altered transcriptional regulation of the BRCA1 gene, 11, 12 suggesting that the control of BRCA1 transcription might be important to tumorigenesis. Although several groups have demonstrated that the BRCA1 promoter is regulated by transcriptional co-activators and co-repressors, [13] [14] [15] as well as methylation of specific CpG islands, 16 the mechanism regulating BRCA1 expression remains largely unknown.
E2F1 is a member of the E2F gene family of transcription factors, which regulate the expression of genes involved in a wide range of cellular processes including cell-cycle progression, DNA replication, DNA repair, differentiation and apoptosis. E2F1 can act either as an oncogene or a tumor suppressor, depending on tissue type and experimental conditions. 17 Emerging data suggest that, in addition to having a prominent role in apoptosis, E2F1 may function as a tumor suppressor by promoting DNA damage repair and maintenance of genomic stability. [18] [19] [20] E2F1 promotes DNA repair in transcription-dependent or -independent mechanisms. 21 First, E2F1 transcriptional activity leads to high expression of several DNA repair genes, including BRCA1, RAD51 and RAD52. 14, [22] [23] [24] [25] [26] Second, E2F1 enables the formation of multicomponent protein complexes at sites of damage or recruitment of protein factors. 19, 27, 28 Thus, although it is clear that E2F1 has a direct role in regulating BRCA1 expression, 22 the mechanistic details are currently an enigma.
In an siRNA screen targeting 555 individual E3 ubiquitin ligases, RNF126 was identified as 1 of the 14 proteins required for cell growth through targeting p21 for ubiquitination-dependent degradation. 29 Other reports have shown that RNF126 also targets EGFR 30 and AID for ubiquitylation. 31 Together, these data demonstrate multiple functions of RNF126 associated with a diverse set of cellular processes. The RNF126 gene is mapped to chromosome 19 p13.3 which is a commonly deleted region in ovarian cancer. [32] [33] [34] In addition, high-resolution 19p13.2-13.3 allele typing of breast carcinomas demonstrates frequent loss of heterozygosity. 35 The RNF126 E3 ubiquitin ligase contains a RING finger and a Zinc-finger domain, both of which are common in a variety of functionally distinct proteins and domains that participate in protein-protein and protein-DNA interactions. In addition, RNF126 proteins contain a serine-rich array that is evolutionarily conserved and is similar to that found in transcriptional activators present at RNAPII-dependent promoters. 31 Taken together, recently emerging data hint at an eminent role of RNF126 in transcriptional regulation.
In this report we demonstrate that RNF126 promotes HR. Mechanically, RNF126 enhances transcription of HR protein BRCA1 by binding directly to E2F1. We show that disruption of the RNF126-E2F1 interaction impairs HR and BRCA1 expression by interfering E2F1-mediated transactivation of BRCA1 promoter. In addition, we demonstrate that RNF126 is required for the resistance to PARP inhibitor and IR. Cumulatively, our results define a direct link between RNF126 and HR repair via regulating E2F1-mediated BRCA1 expression. Furthermore, our data demonstrating a direct, functional interaction between E2F1 and RNF126 could provide a novel therapeutic target for cancer therapy.
RESULTS

RNF126 promotes HR
We first determined the role of RNF126 in HR by using MCF7-pDR-GFP, a cell line with a chromosomally integrated HR plasmid substrate DR-GFP as described previously. [36] [37] [38] [39] [40] In this system, a DSB is generated by expressing the I-SceI endonuclease, whose 18-bp recognition site has been integrated into the GFP gene such that it disrupts the gene. Repair of the cleaved I-SceI site by HR gives rise to a functional GFP gene when the template used for repair is a truncated GFP fragment located downstream in the plasmid, and HR activity is measured by flow cytometric analysis of the number of GFP + cells following I-SceI expression. Using two short-hairpin RNAs (shRNAs) targeting different regions in the RNF126 transcript ( Figure 1a ), it was found that RNF126 was involved in HR ( Figure 1b ). Consistent with the magnitude of decrease in protein levels, a greater decrease in HR frequency was observed in cells infected with RNF126 shRNA #3 compared with those infected with RNF126 shRNA #1 ( Figure 1b ). These results provide direct evidence that RNF126 promotes DSB-induced HR. The impaired HR in cells depleted of RNF126 was not caused by alteration of the cell-cycle profile, because almost identical cellcycle profiles were observed in MCF7 cells with or without RNF126 depletion ( Figure 1c ). The effect of RNF126 on HR was further confirmed in U2OS cells with the chromosomal integration of HR substrate DR-GFP (Figure 1d and e). The knockdown of RNF126 by shRNA #3 (Figure 1d ) led to a decrease in I-SceI-induced HR (Figure 1e ). In summary, the results in Figure 1 suggest that RNF126 promotes HR. Because RNF126 depletion by virus infection of shRNA #3 causes more severe RNF126 knockdown compared with #1, we focused on the use of shRNA #3.
RNF126 facilitates BRCA1 gene expression, independent of its E3 ligase activity
To test if the decreased HR was owing to decreased levels of HR proteins, we initially screened the majority of proteins required for HR. BRCA1 protein levels were reduced in MCF7 cells depleted of RNF126 (Figure 2a , left panel). Of note, although the RAD51 level was also slightly decreased the magnitude is much less profound than those observed for BRCA1. However, other screened proteins were unchanged, indicating that RNF126 specifically regulates In support of the hypothesis that RNF126 promotes HR via regulation of the BRCA1 protein level, overexpression of BRCA1 restored the HR deficiency caused by RNF126 depletion (Figure 2b and c). In contrast, depletion of RNF126 did not lead to a significant decrease in HR in BRCA1deficient cells (Supplementary Figure S1 ). In addition, consistent with the role of RNF126 in BRCA1 expression, RNF126 depletion decreased the amplitude of IR-induced foci (IRIF) of BRCA1 by immunostaining (Figure 2e , left panel). Similarly, RNF126 depletion reduced the percentage of cells with RAD51 foci (Figure 2e , right panel), which is consistent with the report that BRCA1 regulates HR by promoting RAD51 recruitment. 41 In addition, the lower RAD51 expression could also contribute to the impaired RAD51 IRIF. Representative IRIF of BRCA1 and RAD51 in cells depleted of RNF126 are shown in Figure 2d . A similar result was obtained in a second cell line MDA-MB-231 (data not shown), indicating the lower BRCA1 protein expression leads to the impaired BRCA1 recruitment.
Next, we determined how RNF126 regulates BRCA1 expression by measuring BRCA1 mRNA levels. RNF126 likely regulates BRCA1 at the transcriptional level, because RNF126 depletion resulted in a decrease in the BRCA1 mRNA level (Figure 2f ). The effect of RNF126 on BRCA1 expression was further supported by an overexpression experiment in which Flag-RNF126 overexpression led to increased mRNA level of BRCA1 compared with control cells (Figure 2g and h). Most importantly, the E3 ligase activity of RNF126 appears to be dispensable for the regulation of BRCA1 expression, because the expression of a validated RNF126 E3 ligase mutant (RNF126-C229A/-C232A) 29 retained the ability to increase BRCA1 protein expression ( Figure 2i ). In summary, the results in Figure 2 suggest that RNF126 promotes recruitment of BRCA1/RAD51 and HR owing to its regulation of BRCA1 mRNA expression.
The role of RNF126 in promoting BRCA1 expression and BRCA1 recruitment depends on E2F1 Given that E2F1 is a well-known transcription factor of BRCA1 promoter, we next examined whether E2F1 is involved in RNF126- mediated regulation of BRCA1 expression. A cell clone with a stable E2F1 knockdown (MCF7-E2F1sh) was generated by BS/U6-E2F1 RNAi transfection and subsequent selections. Effective E2F1 knockdown was verified by western blot (Figure 3a ). Depletion of RNF126 considerably decreased the BRCA1 mRNA level in control MCF7 cells, but RNF126 depletion causes a much less decrease of BRCA1 mRNA in MCF7-E2F1sh cells ( Figure 3b ). In support of this result, the decreased protein level of BRCA1 owing to RNF126 depletion was partially abrogated in cells with a stable E2F1 knockdown ( Figure 3c ). Moreover, the dependence of E2F1 was further confirmed by immunostaining assay, indicating that depletion of RNF126 had no obvious effect on IRIF of BRCA1, although a reduced percentage of BRCA1 IRIF was observed in control cells ( Figure 3d ). Therefore, we conclude that RNF126 regulated BRCA1 expression through E2F1.
RNF126 promotes E2F1-mediated transactivation of the BRCA1 promoter
The requirement of E2F1 for RNF126-induced BRCA1 expression promoted us to investigate whether the E2F1 transactivation activity for BRCA1 promoter is facilitated by RNF126. We first tested this hypothesis by using a luciferase reporter driven by a BRCA1 promoter. 22 Indeed, RNF126 overexpression enhanced the luciferase activity in cells with E2F1 co-expression ( Figure 4a -c left panel) although no significant increase was observed when sole RNF126 was overexpressed (Figure 4c , right panel).
We further determined the occupancy of E2F1 on the BRCA1 promoter by chromatin immunoprecipitation (ChIP), as described previously, 42 in the presence or absence of RNF126 overexpression. A much more profound increase in E2F1 on BRCA1 promoter was detected when Flag-RNF126 and HA-E2F1 were co-overexpressed (Figure 4d , left panel) whereas a less enrichment of E2F1 on BRCA1 promoter was found in cells overexpressing only E2F1 (Figure 4d , right panel). In addition, no obvious recruitment of RNF126 protein on BRCA1 promoter was observed ( Figure 4e ). In further support of our hypothesis, RNF126 depletion reduced the enrichment of E2F1 on BRCA1 promoter ( Figure 4f ). Taken together, Figure 4 suggested that RNF126 promotes transactivation activity of E2F1 via facilitating the binding of E2F1 to BRCA1 promoter.
RNF126 directly binds to E2F1
In order to understand the mechanisms by which RNF126 promotes E2F1-mediated transactivation in detail, we next determined if RNF126 interacts with E2F1 by co-immunoprecipitation. Indeed, an interaction between endogenous RNF126 and E2F1 was detected by reciprocal co-immunoprecipitation in MCF7 cells (Figure 5a ). This result was further confirmed by exogenous overexpression assay. In brief, Flag-RNF126 was overexpressed in MCF7 cells. E2F1 was found in the anti-Flag immunoprecipitates (Figure 5b ( Figure 5c , upper blot). The membrane was reprobed with anti-GST antibody for a control purpose (Figure 5c lower blot). Most importantly, an in vitro GST pull-down assay showed a further direct binding between RNF126 and His-E2F1 ( Figure 5d ). Following incubation of GST-RNF126 and His-E2F1 prepared from bacteria, GST-RNF126 pulled down by the GST column was probed with an antibody to His and revealed that a GST-RNF126 retained His-E2F1 protein (Figure 5d , upper lane), indicating that the interaction of these two proteins was direct. The membrane was reprobed with antibodies against RNF126 (middle panel) or GST for a control purpose (third panel).
In order to map the E2F1-binding domain in RNF126, a series of RNF126 mutants were generated as indicated in Figure 5e (left panel). Purified GST-E2F1 efficiently pulled down Flag-RNF126-WT and the Flag-RNF126-A, -B, -D and -G mutants but not the RNF126-C, -E and -F mutants (Figure 5e, right panel) , indicating that the residues of RNF126 from 40 to 228 are important for interaction, because this region is deleted in all three RNF126 mutants C, E and F. However, there was a likelihood that the lack of interaction could be caused by lower protein expression because no detectable proteins expression was found for Flag-RNF126-C, -E and -F (Figure 5f , upper panel) even if the film was exposed for a longer period of time (Figure 5f, bottom  panel) . In order to test this possibility, we further generated a series of RNF126-deletion mutants (Figure 5g, left panel) . We narrowed down the interaction region to 11 amino acids (aa) in RNF126 protein from 185 to 195, that is critical for the interaction with E2F1 because GST-E2F1 failed to pull-down RNF126-Δf that lacks the 11 aa from 185 to 195 (Figure 5g, right panel) , although a comparable protein expression was observed in the cells expressing Flag-RNF126-WT or RNF126-Δf (Figure 5h ). Of note, a much lower expression of RNF126-Δb and RNF126-Δe was observed compared with RNF126-WT. Because both mutants lack aa residues 130-140, indicating that these 11 aa are likely important for RNF126 stability (Figure 5h ). However, an interaction of GST-E2F1 and Flag-RNF126-Δb/Δe was still observed (Figure 5g , right panel), indicating that these residues are important for RNF126 stability without affecting the interaction with E2F1. Although future investigation is warranted illustrating the mechanisms causing the degradation of Flag-RNF126-Δb/Δe is out of the scope of the current study. Collectively, these results in Figure 5 suggested that the 11 aa located in RNF126 protein from 185 to 195 are critical for the interaction with E2F1.
RNF126 promotes E2F1-mediated transactivation of BRCA1 via interaction with E2F1 Next, we attempted to determine if the RNF126-Δf mutant lacking the association with E2F1 loses the functions of RNF126. RNF126-Δf overexpression failed to induce a significant increase in luciferase activity driven by the BRCA1 promoter in the cells coexpressing E2F1, whereas overexpression of RNF126-WT led to an increased luciferase activity in the same condition (Figure 6a ). In contrast, RNF126-Δf expression reduced the luciferase activity compared with control cells (Figure 6a ), indicating that RNF126-Δf expression has a dominant-negative effect which may interfere with the function of endogenous RNF126. This result was further supported by a ChIP assay showing that RNF126 overexpression enhanced the enrichment of E2F1 on BRCA1 promoter but RNF126-Δf overexpression resulted in a significant decrease in E2F1 protein binding to BRCA1 promoter (Figure 6b ). The dominant-negative effect of RNF126-Δf was further supported by Figure 6c and d, showing that the decreased expression of BRCA1 in both mRNA and protein levels were observed in cells expressing RNF126-Δf compared with controls cells, whereas the increased BRCA1 mRNA and protein expression was found in cells expressing RNF126-WT as described in Figure 2 . Last, dominantnegative effect of RNF126-Δf expression on HR was also observed as indicated in Figure 6e and f. However, we did not see an obvious increase in HR when the RNF126-WT and RNF126 E3 ligase mutant was overexpressed ( Figure 6f ). This could be caused by the following two reasons. First, the HR activity is saturated although RNF126 or BRCA1 protein levels are increased. Second, slight toxicity was observed when RNF126-WT or RNF126-RNF126-C229A/-C232A overexpressed, which is consistent with the well-known biological toxicity caused by BRCA1 overexpression 19 that may prevent us from seeing the increased HR frequency in cells overexpressing RNF126. To test this hypothesis, we overexpressed RNF126-Δf in cells treated with siRNA targeting the untranslated region of RNF126, and we found that the overexpression of RNF126-Δf failed to restore the decreased HR owing to RNF126 depletion, although expression of RNF126-WT successfully restored HR activity (Figure 6g ). Taken together, the results described in Figure 6 strongly suggested that via the interaction with E2F1, RNF126 promotes E2F1-mediated BRCA1 expression and HR. In addition, expression of the RNF126 mutant lacking the interaction with E2F1 has a dominant-negative effect on BRCA1 expression.
RNF126 is required for the resistance to PARP inhibitor and IR Defect in HR leads to an enhanced sensitivity to chemotherapeutic drugs, as well as IR. To test the hypothesis that RNF126 depletion may sensitize cells to PARP inhibitor due to its role in HR, we determined whether RNF126 has a role in the resistance to the PARP inhibitor ABT-888. The survival of cells depleted of RNF126 was reduced in MCF7 cells (Figure 7a ). Also, an enhanced sensitivity to IR was observed in MCF7 depleted of RNF126 (Figure 7b ), suggesting that RNF126 is required for cell survival after PARP-inhibitor treatment and IR exposure. However, the magnitude of decrease in cell survival following PARP-inhibitor treatment and IR exposure is less than that observed in BRCA1deficient cells (data not shown). We speculated that targeted inhibition of RNF126 sensitized cells to PARP inhibition and IR exposure due to an effect on apoptosis reduction, given that it has been shown that E2F1 also regulates several pro-apoptotic genes.
In order to test the hypothesis, we assayed its effect on the expression of apoptotic gene p73 in 293T cells, in which apoptosis has been shown to be specifically dependent on E2F1. 43, 44 In support of the idea that RNF126 is important for E2F1-mediated p73 expression, we found that the overexpression of RNF126 leads to an increase in level of p73 mRNA when E2F1 is co-overexpressed (Supplementary Figure S2A) . In order to test the occupancy of E2F1 on p73 promoter, we performed ChIP in 293T cells. We found an increased HA-E2F1-protein occupancy on p73 promoter when RNF126 and E2F1 were co-overexpressed, indicating that RNF126 enhanced the binding of E2F1 to p73 promoter (Supplementary Figure S2B ). In addition, a similar result was seen for caspase 7, another E2F1-target apoptosis gene. We found that RNF126 enhanced the occupancy of E2F1 on caspase 7 promoter (Supplementary Figure S2C) . These data suggested a role for RNF126 in promoting the expression of apoptosis genes regulated by E2F1. Of note, we are not pursuing to investigate if a RNF126 depletion cause a decreased apoptosis because of the role of RNF126 in HR repair may counteract its action in promotion of E2F1-mediated apoptosis. Together, we concluded that RNF126 is important for resistance to IR and PARP1-inhibitor resistance, although RNF126 also regulates other E2F1-target genes involved in apoptosis.
DISCUSSION
Germ-line mutations in the BRCA1 tumor suppressor gene contribute to hereditary breast and ovarian cancer syndrome. In addition, decreased expression of the BRCA1 gene is common in sporadic breast and ovarian tumors, and the magnitude of the decrease correlates with disease progression. Identify how these regulators which controlling BRCA1 expression, could lead to a better understanding of sporadic breast/ovarian cancer etiology, and the generation of novel therapeutic strategies targeting sporadic breast/ovarian tumors. In our study, we identify a novel role of RNF126 in HR via regulation of E2F1-dependent BRCA1 expression ( Figure 7c ).
HR-mediated DSBs repair is a key mechanism required for tumor suppression by maintaining genomic stability. The finding that RNF126 promotes HR via regulating BRCA1 expression Figure 6 . Expression of RNF126-Δf inhibits BRCA1 expression and HR by interfering the binding of E2F1 to BRCA1 promoter. (a) RNF126-Δf expression suppresses E2F1-mediated transactivation on BRCA1 promoters. E2F1 transactivation activity was measured with a BRCA1 promoter-luciferase activity in MCF7 cells as described in Figure 4c . Results are means from three independent experiments, with s.e.m. (t-test, *P o0.05; **P o0.01). (b) Enrichment of E2F1 for the BRCA1 promoter was assessed by quantitative PCR. The 293T cells with indicated protein expression were subjected to ChIP assay using a mouse HA antibody, or control normal rabbit IgG. Input DNA and protein-bound DNA fragments were amplified with BRCA1 primer pairs. Results are means from three independent experiments, with s.e.m. (t-test, *Po 0.05; **P o0.01). (c) RNF126-Δf expression suppress BRCA1 mRNA expression in 293T cells. The RT-PCR was performed as described in Figure 2f (d) RNF126-Δf expression suppresses BRCA1 protein expression in MCF7 cells. (e) BRCA1 expression in the cells with RNF126-WT or RNF126-Δf or RNF126-C229A/-C232A overexpression. (f) The relative HR frequencies in cells expressing RNF126-Δf are shown vs cells expressing RNF126-WT or RNF126-C229A/-C232A. HR was performed as described in Figure 1 . Results are means from three independent experiments, with s.e.m. (t-test, *P o0.05). (g) Flag-RNF126-Δf expression failed to restore the impaired HR owing to RNF126 depletion. In brief, silencing of endogenous RNF126 was accomplished by a siRNA targeting the RNF126 3′-untranslated region of messenger RNA. Then the exogenous RNF126 was introduced into cells. HR was determined as described in Figure 1 . Error bars show s.e.m. from three independent experiments (t-test, *P o0.05). RNF126 expression was monitored by western blot.
( Figures 1 and 2) suggested a potential mechanism regulating BRCA1 gene expression. The question as to whether RNF126 could function as a tumor suppressor by functioning in BRCA1-mediated HR and whether a subtype breast/ovarian cancer display a lower BRCA1 expression owing to RNF126 deficiency needs to be determined in clinical settings.
We identified a new function of RNF126 in transcriptional regulation of BRCA1 gene by acting as a regulator of E2F1 (Figures 3, 4, 5, 6) . The tandem array of serines at the very C terminus of RNF126 is homologous to similar serine stretches found in transcriptional activators present at RNAPII-dependent promoters. 31 Thus, the existence of serine array in RNF126 suggested that RNF126 may act as a transcriptional activator by the corporation with other transcriptional factors. Our results strongly support this hypothesis by demonstrating that RNF126 facilitates the transacriptional activity of E2F1 on BRCA1 promoter via a direct interaction with E2F1. Nevertheless, the nature of interaction of RNF126 and E2F1 is not clear. Given that E2F1 is important for the chromatin remodeling, 45 it would be very interesting to determine if chromatin remodeling is regulated by RNF126 via interaction with E2F1, which could be a potential mechanism promoting BRCA1 expression. Of note, E3 ligase activity of RNF126 appears to be not important for RNF126mediated BRCA1/HR regulation (Figures 2i and 6e ). However, we cannot exclude the possibility that E3 ligase activity is required for ubiquitination of multiple proteins which oppositely affects BRCA1 expression/HR. Thus, no obvious effect on HR/BRCA1 expression was observed in cells expressing E3 ligase mutant.
Consistent with its role in HR, RNF126 contributes to the resistance to IR and PARP inhibitor (Figure 7) . Given the fact that cisplatin is the initial treatment for 90% ovarian cancer patients, and HR is important for repairing DNA damage caused by platinum drugs, this result could suggest that RNF126 deficiency could be a predicative marker for the better outcome of cancer therapy. Interestingly, The Cancer Genome Atlas (TCGA) data suggest that homozygous and/or heterozygous deletion of RNF126 gene is observed in a broad spectrum of human tumors. 46, 47 For instance, the large majority of ovarian serous cystadenocarcinoma which accounts for the largest proportion of malignant ovarian tumors display either homozygous or heterozygous deletion of the RNF126 gene (Supplementary Figure  S3A) . 46, 47 Intriguingly, tumors with decreased expression of RNF126 correlated with improved disease-free (P o 000001; Supplementary Figure S3B ) and overall survival (Po 0.0001; Supplementary Figure S3C ). 46, 47 In addition to deletion and low mRNA expression, the mutations of RNF126 are also observed in a variety of human tumors, indicating that the RNF126 inactivation may broadly exist in human tumor. 46, 47 Therefore, it could be possible that RNF126 are inactive in cancer patients due to deletion or mutation or low mRNA expression. Overall, this data highlights the clinical relevance of RNF126 and indicates that RNF126 may serve as a relevant therapeutic target for novel therapies for serous ovarian cancer patients.
In addition to BRCA1, other E2F1-target genes such as apoptosis genes are also regulated by RNF126 ( Supplementary Figure S2) . It is conceivable that RNF126 deficiency on one hand impaired DSB repair pathway and on the other hand impairs apoptosis. Thus, the alteration in the expression of apoptosis gene could counteract to the cell death caused by the defect of DNA repair. In addition, the proteins regulating anti-apoptosis could also be a target of RNF126. For instance, EGFR1, a protein required for the antiapoptosis-protein expression, can be targeted for degradation by RNF126. 30 The further work should focus on how to identify the population which dominated control by RNF126-mediated DNA repair pathway instead of its effect on apoptosis activity or vice versa. This information would help to identify the special group with a deregulated RNF126 expression to be specifically targeted by radiation therapy and PARP inhibitor-related therapy.
In addition to pRb family members, which have long been considered to be the major regulators of E2F1, TOPBP1 and MCPH1 are recently found to be a new class of regulators for E2F1. However, these two proteins have opposite role in apoptosis. 28, 42 Our studies apparently provides a strong evidence suggesting that RNF126 is a novel factor regulating E2F1-dependent transcriptional activities. Additional work will be required to determine the composition of different RNF126/E2F1-containing complexes and their unique functions in E2F1-mediated transcriptional regulation.
In summary, we have identified a novel function of RNF126 in HR. In addition, our study links RNF126 to BRCA1, one of the most important tumor suppressor genes in breast and ovarian cancers, by demonstrating that RNF126 promotes E2F1-dependent BRCA1 expression via a direct interaction with E2F1 ( Figure 7c ). Our study offers novel insights into our current understanding of biological function of RNF126 and provides a potential target for cancer therapy.
MATERIALS AND METHODS
Cell lines, infections and transfections
MCF7, MDA-MB-231, 293T and U2OS cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% bovine calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C, 5% CO 2 . The shRNA of RNF126 were purchased from Sigma-Aldrich (St Louis, MO, USA). Targeting region of RNF126 shRNA126 #1 and shRNA #3 are 5′-TGCATGGTTTGTGGCGGAAGA-3′ and 5′-GCAACGAGAACGCCACATGGT-3′, respectively. The control siRNA and RNF126 siRNA were obtained directly from Integrated DNA Technologies (IDT, Coralville, IA, USA). RNF126 siRNA targets the untranslated region of RNF126 mRNA, and target region is 5′-CTCTGTCTAACCTCACCCTCTAAAC -3′. The full-length wild-type RNF126 and RING-domain mutated (C229A/ C232A) RNF126 were described previously. 29 HA-E2F1 and GST-E2F1 were kindly provided by Dr Matthew Summers (Cleveland Clinic, Cleveland, OH, USA) and Dr Weei-Chin Lin (Baylor College of Medicine, Houston, TX, USA), respectively. The His-E2F1 was a gift from Maria Alvarado-Kristensson (Skåne University Hospital, Malmö, Sweden). The adenoviral I-SceI endonuclease Ad-SceI-NG expression vector was obtained from Kristoffer Valerie (Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA). The BRCA1-promoter reporter was a gift from David G. Johnson (MD Anderson Cancer Center, University of Texas, Austin, TX, USA). U2OS cells with the chromosomal integration of HR substrate DR-GFP was provided by Zhongsheng You (Washington University School of Medicine, St Louis, MO, USA). All the DNA-plasmid transfections were performed using Lipofectamine 2000 according to the manufacturer's recommendations (Invitrogen).
To generate Flag-RNF126 construct, the full-length RNF-126 fragment was amplified by PCR from pGEX-6P-1 vector expressing RNF126, 29 and subcloned into vector pCMV-3Tag-1A (3xFlag-tagged) using the EcoRI and XhoI, and the primer sets P1 (5′-AAAAGAATTCGCCGAGGCGTCGCCGCATCC-3′) and P2 (5′-AAAACTCGAGTCACGAGTTGCTTGTGGCGTTCTCG-3′); To generate GST-RNF126 construct, the full-length RNF-126 was subcloned into vector pCMV-3Tag-1A (GST-tagged) using the BamHI and XhoI, and the primer sets P1 (5′-AAAAGGATCCGCCGAGGCGTCGCCGCATCC-3′) and P2 (5′-AAAACTCGAG TCACGAGTTGCTTGTGGCGTTCTCG-3′).
To generate a series of deletional mutant RNF126-B, -C, -D, -E and -F, QuikChange II Site-Directed Mutagenesis Kit (cat number 200523, Stratagene, Santa Clara, CA, USA) was used. To generate a series of deletional mutant RNF126-Δa, b, c, d, e and f, QuikChange Lightning Site-Directed Mutagenesis Kit (cat number 210518, Stratagene) was used. The primers used to generate RNF126 mutation are available upon request.
To generate cell lines with E2F1 stable knockdown, MCF7 cells were transfected with empty BS/U6 RNAi vector or with BS/U6-E2F1 RNAi vector together with pcDNA-3, which encodes a neomycin-selectable marker. BS/U6 RNAi vector and BS/U6-E2F1 RNAi vector are gifts from Cress WD (The H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA). The details was described in our previous publication. 37 HR assays HR was measured in MCF7-pDR-GFP cells by flow cytometry as described previously. 39 
Cell-cycle analysis
Cell-cycle analysis was conducted as we described previously. 39 Real-time quantitative reverse transcription-polymerase chain reaction Real-time quantitative reverse transcription-polymerase chain reaction was conducted as per our previous publication. 39 BRCA1 forward primer 5′-GAA ACCGTGCCAAAAGACTTC-3′. BRCA1 reverse primer: 5′-TCACAA GCAGCCAATTCAATGT-3′. p73 forward primer and reverse primer are described in a previous publication. 42 
Immunofluorescence analysis
Immunofluorescence assays were performed as published. 39 Immunoprecipitation and immunoblotting Immunoprecipitation and immunoblotting was conducted as described previously. 37, 48 GST fusion proteins and pull-down assay GST pull-down assay was performed according to our previous publication. 39 
Dual-luciferase assays
Dual-luciferase assays were conducted as we described previously. 49 
ChIP assay
ChIP assays were performed as previously described. 42 Clonogenic-survival assays Clonogenic-survival assays were performed according to our previous publications. 37, 39 Antibodies
